Literature DB >> 8086373

Adoptive transfer of a Th2-like cell line prolongs MHC class II antigen disparate skin allograft survival in the mouse.

H Maeda1, M Takata, S Takahashi, S Ogoshi, S Fujimoto.   

Abstract

The MHC class II alloantigen-reactive CD4+ Th2-like cell line, HR2, was established. It was derived from the spleen cells of C57BL/6 (B6) mice immune to an MHC class II-disparate mutant mouse, B6.CH-2bm12 (bm12) which carries the I-Abm12 antigen. This cell line, HR2, secretes IL-4 and IL-10 in an antigen-specific manner, and can also proliferate in an autocrine manner through IL-4. To investigate the in vivo role of this Th2-like CD4+ T cell line in transplantation immunity, an adoptive cell transfer study using the skin allograft system was performed. Skins grafted from bm12 to B6 were rejected at 12.1 +/- 0.6 days in control B6 mice which received no treatment. Whereas skin graft survival was prolonged in B6 experimental mice which had received 2 x 10(7) HR2 cells, 75% of the grafts survived for > 40 days. Moreover, since skin grafts from fully allogeneic third party donor BALB/c mice were rejected at 12.0 +/- 0.4 days by B6 mice which had received the same number of HR2 cells, it was demonstrated that HR2 is involved in the regulation of bm12 skin graft rejection. Furthermore, cytotoxic T lymphocyte (CTL) activity by spleen cells from HR2 transferred B6 mice was not induced even by in vitro secondary stimulation, although CTL activity was induced well in spleen cells of control B6 mice which had rejected the graft. The underlying mechanism has not been fully clarified; however, these results demonstrate that Th2-like CD4+ T cells suppress allograft rejection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8086373     DOI: 10.1093/intimm/6.6.855

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  8 in total

Review 1.  Allograft rejection results from a failed attempt by the immune system to protect foreign tissue.

Authors:  D S Hall; E Roberts; J Davies
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

Review 2.  Th1/Th2 balance in cancer, transplantation and pregnancy.

Authors:  M R Shurin; L Lu; P Kalinski; A M Stewart-Akers; M T Lotze
Journal:  Springer Semin Immunopathol       Date:  1999

3.  IL-4 expression delays eosinophil-independent vasculopathy and fibrosis during allograft rejection in the mouse.

Authors:  Edda M Roberts; De Shon Hall; Sharon Ferguson; Susan Minson; Joanna D Davies
Journal:  J Clin Immunol       Date:  2003-03       Impact factor: 8.317

Review 4.  Lung transplantation: infection, inflammation, and the microbiome.

Authors:  Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn
Journal:  Semin Immunopathol       Date:  2011-01-27       Impact factor: 9.623

5.  Tolerance to solid organ transplants through transfer of MHC class II genes.

Authors:  K C Sonntag; D W Emery; A Yasumoto; G Haller; S Germana; T Sablinski; A Shimizu; K Yamada; H Shimada; S Arn; D H Sachs; C LeGuern
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

6.  Suppressor T cells regulate the nonanergic cell population that remains after peripheral tolerance is induced to the Mls-1 antigen in T cell receptor Vbeta 8.1 transgenic mice.

Authors:  H Maeda; S Fujimoto; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

7.  Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies.

Authors:  Hauke Winter; Hong-Ming Hu; Christian H Poehlein; Erik Huntzicker; John J Osterholzer; Jaffar Bashy; David Lashley; Bruce Lowe; Jane Yamada; Gregory Alvord; Walter J Urba; Bernard A Fox
Journal:  Immunology       Date:  2003-03       Impact factor: 7.397

8.  Cytokines in clinical and experimental transplantation.

Authors:  A C Vossen; H F Savelkoul
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.